 |
|
Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease
Glenda M. Halliday, PhD;
Claire E. Shepherd, PhD;
Heather McCann, DipHealthSc;
Wayne G. J. Reid, PhD;
David A. Grayson, PhD;
G. Anthony Broe, FRACP;
Jillian J. Kril, PhD
Arch Neurol. 2000;57:831-836.
Background There has been no analysis of brain tissue from longitudinally observed, cognitively tested patients to validate whether anti-inflammatory medications protect against the pathological changes of Alzheimer disease.
Objective To investigate the role of anti-inflammatory medications in alleviating the pathological features of Alzheimer disease.
Design and Main Outcome Measures A 5-year postmortem tissue collection was performed after a case-control study of Alzheimer disease (approximately 90 [30%] of patients died during follow-up, of whom consent for autopsy was obtained in 44 [50%]). Cases were selected on the basis of (1) adequate clinical histories of nonsteroidal anti-inflammatory drug usage, (2) no neuropathological findings other than Alzheimer disease, and (3) no generalized sepsis at death. Variables analyzed included neuropsychological test scores and amount of tissue inflammation and Alzheimer-type pathological changes. Two-way analysis of variance was used to determine whether drug usage significantly affected these variables.
Setting The Centre for Education and Research on Ageing and the Prince of Wales Medical Research Institute, Sydney, Australia.
Patients Twelve patients with Alzheimer disease (5 taking anti-inflammatory drugs) and 10 nondemented controls (3 taking anti-inflammatory drugs) were selected (50% of available sample).
Results Of the patients with Alzheimer disease, anti-inflammatory drug users performed better on neuropsychological test scores than did nonusers. However, there were no significant differences in the amount of inflammatory glia, plaques, or tangles in either diagnostic group.
Conclusion Long-term anti-inflammatory medications in patients with Alzheimer disease enhanced cognitive performance but did not alleviate the progression of the pathological changes.
From the Neuropathology Laboratory, Prince of Wales Medical Research Institute, Randwick, Australia (Drs Halliday and Shepherd and Ms McCann), and Centre for Education and Research on Ageing, University of Sydney and Concord Hospital, Concord, Australia (Drs Reid, Grayson, Broe, and Kril).
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(6):902-904.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology
Arvanitakis et al.
Neurology 2008;70:2219-2225.
ABSTRACT
| FULL TEXT
William M. Feinberg Lecture: Cognitive Vitality and the Role of Stroke and Cardiovascular Disease Risk Factors
Gorelick
Stroke 2005;36:875-879.
ABSTRACT
| FULL TEXT
Risk Factors for Vascular Dementia and Alzheimer Disease
Gorelick
Stroke 2004;35:2620-2622.
ABSTRACT
| FULL TEXT
Cerebrovascular Transforming Growth Factor-{beta} Contributes to Inflammation in the Alzheimer's Disease Brain
Grammas and Ovase
Am. J. Pathol. 2002;160:1583-1587.
ABSTRACT
| FULL TEXT
Microglial Activation and beta -Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice
Jantzen et al.
J. Neurosci. 2002;22:2246-2254.
ABSTRACT
| FULL TEXT
Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease
Mackenzie et al.
Arch Neurol 2001;58:517-518.
FULL TEXT
|
